The purpose of HTA is to provide high-quality information to decision makers about the clinical effectiveness, cost-effectiveness, and broader impact of drugs, medical technologies, and health systems.
Manufacturing biological medicines is generally more complex than the production of traditional (
The biotech industry proposes the development of shared European standards for HTAs to ensure the
Innovative medicines generally benefit from a certain period of intellectual property protection
Biosimilar medicines are follow-on versions of original biological medicines.